Reduced annexin A6 expression promotes the degradation of activated epidermal growth factor receptor and sensitizes invasive breast cancer cells to EGFR-targeted tyrosine kinase inhibitors

Rainelli B Koumangoye1,2, Gladys N Nangami1, Pamela D Thompson1, Vincent K Agboto3, Josiah Ochieng1 and Amos M Sakwe1*

Abstract

Background: The expression of annexin A6 (AnxA6) in AnxA6-deficient non-invasive tumor cells has been shown to terminate epidermal growth factor receptor (EGFR) activation and downstream signaling. However, as a scaffolding protein, AnxA6 may stabilize activated cell-surface receptors to promote cellular processes such as tumor cell motility and invasiveness. In this study, we investigated the contribution of AnxA6 in the activity of EGFR in invasive breast cancer cells and examined whether the expression status of AnxA6 influences the response of these cells to EGFR-targeted tyrosine kinase inhibitors (TKIs) and/or patient survival.

Results: We demonstrate that in invasive BT-549 breast cancer cells AnxA6 expression is required for sustained membrane localization of activated (phosho-Y1068) EGFR and consequently, persistent activation of MAP kinase ERK1/2 and phosphoinositide 3-kinase/Akt pathways. Depletion of AnxA6 in these cells was accompanied by rapid degradation of activated EGFR, attenuated downstream signaling and as expected enhanced anchorage-independent growth. Besides inhibition of cell motility and invasiveness, AnxA6-depleted cells were also more sensitive to the EGFR-targeted TKIs lapatinib and PD153035. We also provide evidence suggesting that reduced AnxA6 expression is associated with a better relapse-free survival but poorer distant metastasis-free and overall survival of basal-like breast cancer patients.

Conclusions: Together this demonstrates that the rapid degradation of activated EGFR in AnxA6-depleted invasive tumor cells underlies their sensitivity to EGFR-targeted TKIs and reduced motility. These data also suggest that AnxA6 expression status may be useful for the prediction of the survival and likelihood of basal-like breast cancer patients to respond to EGFR-targeted therapies.

Keywords: Annexin A6, EGFR, Tyrosine kinase inhibitors, Basal-like breast cancer, Metastasis

Background

Annexin A6 (AnxA6), a structurally unusual member of the annexin family of calcium-dependent phospholipid binding proteins, interacts with cellular membranes in a manner that is distinct from other annexins [1]. AnxA6 has also been shown to be down regulated in end-stage heart failure [2], during chronic atrial fibrillation [3] and in malignant forms of melanomas [4]. We recently also showed that AnxA6 is down regulated in breast invasive ductal carcinomas and even more so in breast adenocarcinomas [5]. The unifying characteristic of these conditions is that the highly regulated Ca\(^{2+}\) entry into cells is uncoupled in cells that either lack, or express low levels of AnxA6. The resulting increase in cytosolic Ca\(^{2+}\) in these cells underlies at least in part, the increased contractility of cardiomyocytes [6] and enhanced proliferation of tumor cells [5,7] as well as AnxA6-modulation of tumor cell proliferation, differentiation and motility. While reduced expression
of AnxA6 enhances cell proliferation [5,7] lack of or reduced expression of the protein has been shown to be associated with a decrease in the migration of invasive breast cancer cells (BCCs) [5] and chick cranial crest cells [8]. Meanwhile, loss of AnxA6 was associated with a delay in terminal differentiation of murine growth plate chondrocytes due to decreased expression of terminal differentiation markers [9]. This suggests that AnxA6 is a tumor suppressor and a metastasis promoting factor. However, available evidence does not suggest a direct involvement of AnxA6 in these cellular functions. AnxA6 presumably modulates these cellular functions as a scaffolding protein by influencing the localization, expression levels and/or activity of other cellular factors.

The expression of epidermal growth factor receptor (EGFR) in basal-like breast cancer is associated with poor prognosis [10-12] but more importantly, it provides the possibility to therapeutically target the receptor using either tyrosine kinase inhibitors (TKIs) or therapeutic monoclonal antibodies [13,14]. Although EGFR levels are elevated in several cancers, its prognostic and therapeutic significance in various cancers is quite variable. This is presumably due to the association of patient survival with the total receptor rather than the activated receptor levels [15]. It is also possible that the relatively modest EGFR prognostic value in some cancers including breast cancer, may be due to the modulation of its cellular levels and activity by amongst other cellular factors scaffolding proteins such as MUC4 [16] and AnxA6 [17-20].

AnxA6A is largely considered to be a tumor suppressor. This is based on a number of reports that have amply demonstrated that over expression of the protein in the non-invasive A431 epidermoid carcinoma cells as well as BT20 and MDA-MB-468 breast cancer cells that either lack, or express low levels of AnxA6 inhibited their growth [20]. On the other hand, down regulation of AnxA6 in MDA-MB-436 [20] and BT-549 [5] both of which express high levels of AnxA6, led to increased anchorage-independent growth. The inhibition of tumor cell proliferation following the expression of AnxA6 in AnxA6-low cells has been shown to be partly due to the inactivation of activated EGFR and the termination of EGFR-mediated activation of the Ras pathway. These studies revealed that the AnxA6-mediated inactivation of activated EGFR and inhibition of the Ras signaling pathway were respectively mediated via the interaction of AnxA6 with activated protein kinase C (PKC)-α [21] and p120GAP, the Ras-specific guanine nucleotide activating protein [19,22]. The enhanced growth of AnxA6-deficient tumor cells on the other hand is currently believed to be driven by the high cytosolic Ca²⁺-induced activation of PKC isoforms that in turn activate the Ras pathway independently of EGFR activity [20,23]. Besides these findings, other reports have suggested that by acting as a link between the actin cytoskeleton and the plasma and endosomal membranes [7,24,25], its involvement in vesicular transport [26,27] and localization in cholesterol-rich lipid rafts [28,29], AnxA6 on the contrary, contributes to the stabilization of activated receptors on the cell surface [18].

A number of studies have clearly demonstrated that although ligand-activated EGFR is rapidly internalized and degraded in lysosomes [30-32] it can also be recycled back to the plasma membrane [32]. Contrary to its inhibitory effect on EGFR activation and activity in non-invasive tumor cells that either lack, or express low levels of AnxA6 [19,22], we hypothesized that in AnxA6-expressing invasive tumor cells AnxA6 may promote a sustained cell-surface expression of activated EGFR and therefore, persistent receptor activity that drives cell migration. We therefore, investigated the contribution of AnxA6 in the activity of EGFR in invasive breast cancer cells and examined whether the expression status of AnxA6 influences the response of these cells to EGFR-targeted TKIs and/or patient survival. We demonstrate that reduced AnxA6 expression not only promoted rapid degradation of activated EGFR and reduced motility but also sensitized the cells to EGFR-targeted TKIs. We also show that low AnxA6 expression is associated with a better relapse-free survival but poorer overall and distant metastasis-free survival of basal-like breast cancer patients. Together, this demonstrates that the rapid degradation of activated EGFR in AnxA6-depleted invasive tumor cells underlies their sensitivity to EGFR-targeted TKIs and attenuated motility. These data also suggest that AnxA6 expression status may be useful for the prediction of the survival and likelihood of basal-like breast cancer patients to respond to EGFR-targeted therapies.

Results

AnxA6 is required for the localization of activated EGFR on the surface of breast cancer cells

It has been amply demonstrated that AnxA6 [28,29] and EGFR [33-35] are components of lipid raft containing membrane microdomains. It has also been shown that activation of EGFR is independent of AnxA6 expression [23], and that intact lipid rafts were required for the activation of the receptor [35]. Together, this led us to speculate that AnxA6 expression is required for sustained cell surface localization of activated EGFR in BCCs. To test this we first sought to compare the activation and activity of EGFR in the invasive AnxA6 high BT-549 cells with that of the non-invasive AnxA6-low HCC1806 as well as MDA-MB-468 cells (with amplified EGFR expression). We show that the expression of AnxA6 is barely detectable in HCC1806 and MDA-MB-
468 cells compared to BT-549 cells (Figure 1A). Meanwhile, BT-549 and HCC1806 expressed relatively similar levels of total EGFR while the expression of EGFR was at least 3-fold higher in MDA-MB-468 (Figure 1A and B). Interestingly, treatment of these cells with EGF stimulated to varying extents, the autophosphorylation of the receptor on Y1068 (p-EGFR Y1068). Analysis of the time course for the activation of EGFR revealed that the receptor remained strongly activated even after 90 min in MDA-MB-468 cells. The activated receptor

![Figure 1 AnxA6 is required for the localization of activated EGFR on the surface of breast cancer cells. A) BT-549, HCC1806 and MDA-MB-468 cells were grown to 70% confluency, followed by serum starvation for 24 h. Cells were then treated with EGF for 0–90 min and harvested by scrapping in ice-cold PBS. Equal amounts of whole cell lysates were separated in 4–12% polyacrylamide gels under reducing conditions and analyzed by Western blotting with the indicated antibodies. B) Densitometric analysis of EGFR expression. Bars represent EGFR expression relative to BT-549 cells from at least three independent experiments. C) Densitometric analysis of EGF-induced EGFR activation. Points represent activated EGFR (p-Y1068) relative to untreated control cells from at least three independent experiments. D) AnxA6 expression promotes a sustained cell surface localization of activated EGFR in breast cancer cells. BT-549, HCC1806 and MDA-MB-468 cells were grown on glass cover slips in complete DMEM/F12 medium, then serum-starved overnight. The cells were subsequently washed twice in Hanks’ balanced salt solution (HBSS) and then treated with or without EGF for 5 min. The cells were then fixed for 20 min in 3% paraformaldehyde in PBS. Activated EGFR was detected by immunofluorescence staining with antibodies to phospho-EGFR (Y1068) and counterstained with DAPI. Bars = 10 μm.](image-url)
levels however, decreased with time in both HCC1806 and BT-549 cells (Figure 1C). Figure 1A also shows that in the AnxA6-high BT-549 cells, the activation of EGFR led to a sustained activation of MAP kinase ERK1/2 (p-ERK1/2). Paradoxically, in the AnxA6-low HCC1806 and MDA-MB-468 cells and compared to BT-549 cells, EGFR activation led to relatively reduced activation of ERK1/2 (Figure 1A).

To explain this paradox, we examined the localization of the activated receptor in the three cell lines by immunofluorescence. As shown in Figure 1D, there was a robust EGF-stimulated activation of EGFR in the AnxA6-low MDA-MB-468 cells. Interestingly, the activated EGFR in these cells was essentially localized to the perinuclear/cytoplasmic regions (red arrow heads) and in some cells, sequestered into the nucleus (white arrow head). Similarly, and consistent with Figure 1A, in the AnxA6-low HCC1806 cells, plasma membrane-localized activated EGFR (red arrow head) was also barely detectable (Figure 1D). On the contrary, in the AnxA6-high BT-549 cells, the activated EGFR was predominantly localized to the plasma membrane (red arrow heads). These data suggest that AnxA6 enhances the localization of activated EGFR on the cell surface and that this is accompanied by sustained activation of down-stream effectors such as ERK1/2.

To further ascertain the requirement of AnxA6 in the sustained localization of activated EGFR at the cell surface, and whether this is required for the invasiveness of these cells, we used RNA interference to down-regulate AnxA6 in the AnxA6-high BT-549 cells. Two AnxA6-depleted cell lines designated BT-A6sh2 (clone A1) and BT-A6sh5 (clone A3) were selected from 10 different clones (Additional file 1: Figure S1) and respectively showed ~30% and >80% AnxA6 depletion by Western blotting (Figure 2A). The AnxA6-depleted cells grew more slowly than the control cells (Figure 2B) and as previously shown [5], their motility was significantly inhibited (Figure 2C). As shown in Figure 2D AnxA6 depletion also induced a transformation and attenuated activity of the receptor in the non-invasive acinar-like colony morphology in BT-A6sh5 cells. Invasive projections in BT-A6sh5 cells that were discernible were much shorter than those in control cells, suggesting loss of invasiveness. This change in colony morphology is dependent on AnxA6 expression level because BT-A6sh2 cells showed intermediate colony morphologies. Based on these data, the BT-A6sh5 cell line with the most AnxA6 depletion was used as the AnxA6-depleted cell line in most of the following experiments. Interestingly, a similar extent of AnxA6 down regulation in MDA-MB-231 cells did not substantially lead to altered colony morphology and if anything, the cells tended to be more motile than the control cells (Figure 2E-H).

To substantiate the different outcomes of AnxA6 depletion in BT-549 and MDA-MB-231 TNBC cell lines on cell growth and motility, we examined the expression of AnxA6 and EGFR genes in these and other breast cancer cell lines by qRT-PCR. This analysis revealed that MDA-MB-231 cells express relatively reduced levels of both AnxA6 and EGFR compared to BT-549 cells (Additional file 2: Figure S2A and B). We also demonstrate that the response of MDA-MB-231 to EGF treatment is also different from that in BT-549 cells in that while PI3 kinase/Akt and MAP kinase ERK1/2 are strongly activated in BT-549 cells, Akt and to a lesser extent ERK1/2 activation in MDA-MB-231 cells are relatively attenuated (Additional file 2: Figure S2B). As previously reported in other AnxA6-deficient tumor cells [20], over expression of AnxA6 in HCC1806 cells on the other hand was associated with reduced activation of the receptor and ERK1/2 (Additional file 3: Figure S3A-D). AnxA6 expression in HCC1806 cells also inhibited their growth in 3D cultures (Additional file 3: Figure S3E). These data suggest that in triple negative breast cancer cells, the modulation of EGFR activation and/or activity by AnxA6 is not only dependent on the AnxA6 expression levels but is also cell type specific.

Reduced AnxA6 expression promotes the degradation of Activated EGFR

The desensitization of ligand activated EGFR like most cell surface receptors predominantly occur by rapid internalization of receptor-ligand complexes and degradation in lysosomes. Given the strong cell surface expression of activated EGFR in AnxA6 expressing BT-549 cells, we speculated that the virtually absent expression and attenuated activity of the receptor in the AnxA6-low HCC1806 and MDA-MB-468 cells could be attributed to the fate of the activated receptor. To verify this, BT-549 control or AnxA6-depleted cells were treated with or without EGF for 0–90 min, surface biotinylated and the fate of EGFR examined by western blotting. Assessment of the residual levels of biotinylated surface-associated total and pY1068-EGFR in control (AnxA6-high) and AnxA6-depleted (AnxA6-low) BT-549 cells revealed that EGFR activation per se was indeed unaffected by AnxA6 depletion (Figure 3A). As expected, the levels of remaining ligand-activated EGFR decreased with time in both cell lines. However, the residual cell surface-associated activated EGFR decreased more rapidly in AnxA6-depleted cells (BT-A6sh5) compared to that in control cells (Figure 3A and B). By 90 min 60% of the activated EGFR in control cells was still cell surface-associated compared to only 20% in AnxA6-depleted cells. Similarly, the decrease in total cell surface (biotinylated) EGFR in the control cells was initially more rapid but this continued more slowly...
thereafter. On the contrary, there was a transient delay in the down-regulation of biotin-labeled EGFR that was followed by a more rapid decrease in the cell surface EGFR levels (Figure 3A and C). Within 90 min of EGF treatment, the receptor in AnxA6-depleted cells decreased to about 10% compared to about 40% in control cells. Taken together and consistent with data in Figure 1D, these data reveal that AnxA6 depletion in invasive breast cancer cells was accompanied by a rapid decrease in the total and activated cell surface EGFR levels. Furthermore, the transient delay in AnxA6-depleted cells versus a rapid initial decrease in the levels in control cells suggests a role of AnxA6 in the internalization and/or trafficking of the activated receptor.
We next sought to determine whether the rapid decrease in the activated cell surface EGFR in AnxA6-depleted cells and/or the relatively minimal activation of ERK1/2 in either HCC1806 or MDA-MB-468 cells could also be attributed to the lack of or relatively low levels of AnxA6. To do this we examined the residual levels of total EGFR in the AnxA6-depleted and control BT-549 cells. This analysis revealed that the EGF-activated (Figure 4A and B) and the total cellular receptor levels (Figure 4A and C) in control cells remained relatively constant while the receptor levels in AnxA6-depleted cells were not only lower (by at least 3-fold after 90 min), but also decreased more rapidly with time. Densitometric analysis of EGF-stimulated activation of ERK1/2 (Figure 4D) and Akt (Figure 4E) also reveal that these downstream targets were strongly inhibited in the AnxA6-depleted BT-549 cells. This analysis revealed that the EGF-activated receptor (t-EGFR) in AnxA6-depleted cells was restored to those in the control cell by 90 min (Figure 5A and C). To verify whether there were discernible differences in the degradation and recycling of the activated receptor in the control and AnxA6-depleted BT-549 cells, we examined the co-localization of EGF-activated EGFR with either LAMP1 (a late endosomal marker) or Rab11 (a recycling endosomal marker). As depicted in Figure 5E, within 5 min of EGF treatment, cell surface activated EGFR was clearly discernible in the control cells but the cell surface expression was lost by 90 min (arrows). On the contrary, even within 5 min of EGF treatment, most of the activated EGFR was intracellular in AnxA6-depleted cells (Figure 5E, arrows). We also observed a greater extent of co-localization of activated EGFR with LAMP1 in the AnxA6-depleted BT-549 cells compared to the control cells. Meanwhile, the activated receptor co-localized with Rab11 in both the control and AnxA6-depleted cells.
Together these data suggest that activated EGFR is actively recycled in these cells and that EGFR degradation is enhanced in the AnxA6-depleted cells.

AnxA6-depleted invasive breast cancer cells are sensitive to EGFR tyrosine kinase inhibitors

Given that down regulation of AnxA6 in invasive breast cancer cells was accompanied by a decrease in the total and activated EGFR in invasive breast cancer cells, we speculated that AnxA6-depletion in these cells might affect their response to EGFR-targeted TKIs. To explore this further, AnxA6-depleted and control BT-549 cells were treated with various concentrations (0–10 μM) of EGFR-targeted TKIs for 72 h. Figure 6A shows that gefitinib (Iressa) was the least potent of the four compounds while canertinib (CI-1033) was the most potent. In a concentration-dependent manner, AnxA6-depleted BT-549 cells were more sensitive to lapatinib (Tykerb) and PD153035 (Tyrphostin, AG 1517) compared to control cells. As shown in Table 1, the IC50s for inhibition of cell growth for lapatinib and PD153035 were significantly lower in AnxA6-depleted cells compared to control cells. This suggests that reduced AnxA6 sensitizes invasive BCCs to some EGFR-targeted TKIs.

To validate the above data, we compared the response to these compounds of AnxA6-depleted MDA-MB-231 and BT-549 cells as well as AnxA6-over expressing HCC1806 cells with their respective controls. As depicted in Figure 6B, treatment of these cells with these compounds (5 μM) or DMSO control confirmed that while AnxA6 depletion in the invasive BT-549 cells significantly sensitized the cells to lapatinib, PD153035 and canertinib, AnxA6-depletion in MDA-MB-231 cells did not significantly alter their sensitivity to these compounds. Meanwhile, over expression of AnxA6 in HCC1806 did not alter their response to these EGFR-targeted TKIs. Together these data confirm the variable response of breast cancer cells to EGFR targeted...
therapies suggest that reduced AnxA6 expression may be more relevant in breast cancer subtypes such as EGFR expressing invasive basal-like breast cancer.

**AnxA6 expression status is associated with the survival of patients with basal-like breast cancer**

To support the above conclusion, we examined whether AnxA6 expression status also influences the survival of breast cancer patients with varied clinical disease. To do this we used the KM plotter, a recently reported publicly available online survival analysis tool [36] that has been used extensively to analyze the expression of 22,277 genes on the survival of 2,977 breast cancer patients [37-39]. This analysis revealed that, AnxA6 expression status is not associated with the overall (OS), relapse-free (RFS) or distant metastasis-free (DMFS) survival of all breast cancer patients combined (Figure 7A). AnxA6 expression status also is not associated with the survival of patients with luminal breast cancer or those with different HER2, estrogen or progesterone receptor status. However, AnxA6 expression status is significantly associated with the survival of patients with basal-like breast cancer. As shown in Figure 7B, low AnxA6 expression is associated with a significantly higher RFS for patients with basal-like breast cancer (p = 0.023). High AnxA6 levels were on the other hand, are associated with higher OS (p = 0.0024) and DMFS (p = 0.019) for patients with this breast cancer subtype. A previous evaluation of
multiple studies with more than 20,000 patients also showed that high EGFR expression is associated with lower RFS for patients with head and neck, ovarian, cervical, bladder and oesophageal cancers [15]. However, the prognostic value of EGFR expression in other cancers including breast cancer was found to be modest [15].

Discussion
Two opposing notions have thus far emerged from several studies on the potential functions of AnxA6 in cancer progression. On one hand, AnxA6 has been shown to terminate EGFR activity by not only inhibiting the activation of the receptor but also by inhibiting EGFR-induced activation of the Ras pathway [20,23]. This is supported by the inhibition of anchorage-independent growth following over expression of AnxA6 in cells that either lack, or express low levels of the protein [20,23]. On the contrary, there is ample evidence suggesting that AnxA6 contributes to the stabilization of activated receptors on biological membranes that eventually leads to sustained downstream signaling. However, the involvement if any, of AnxA6 in the stabilization of EGFR on the cell surface is as yet unclear. In the present study we showed that AnxA6 is indeed required for the sustained localization of activated EGFR on the surface of invasive...
tumor cells and that this contributes to persistent activation of downstream effectors that drive motility and invasiveness of the cells. This notion is supported by the rapid degradation of activated EGFR, loss of invasiveness and sensitivity to EGFR-targeted TKIs following downregulation of AnxA6 in invasive breast cancer cells. Meanwhile the enhanced proliferation of cells that lack or express low levels of AnxA6 has been shown to be mediated by PKC activation of the Ras pathway independently of EGFR activity [20,23]. Together, these data suggest that while stabilization of activated EGFR by AnxA6 may be important in the dissemination of invasive tumor cells, EGFR activity is dispensable in the enhanced proliferation of cells that either lack, or express low levels of AnxA6. Conflicting data were however, observed following downregulation of AnxA6 in the AnxA6-high BT-549 cells and in MDA-MB-231 cells that expressed comparatively lower levels of the proteins. Given the heterogeneity of breast cancer cells, it is plausible to suggest that the different outcomes of

| EGFR-targeted TKI | BT-549-EV | BT-549-A6sh | Fold change EV:A6sh | P-value EV:A6sh |
|-------------------|-----------|-------------|---------------------|-----------------|
| PD153035          | 6.46 ± 0.62 | 4.16 ± 0.12 | 1.55                | 0.02*           |
| Lapatinib          | 14.09 ± 1.75 | 5.99 ± 1.77 | 2.35                | 0.03*           |
| Canertinib         | 4.30 ± 0.24 | 3.96 ± 0.11 | 1.09                | 0.10            |
| Gefitinib          | 14.43 ± 0.71 | 13.51 ± 2.83 | 1.07                | 0.80            |

IC50 values for EGFR-targeted TKIs in control and AnxA6-depleted invasive breast cancer cells

IC50 - half maximal inhibitory concentration (μM) estimated from the regression plots for the indicated tyrosine kinase inhibitors (TKI). BT-549-EV, control BT-549 cells; BT-549-A6sh, AnxA6-depleted BT-549 cells. For fold change and p-values, EV: A6sh denotes, BT-549 control cells versus AnxA6-depleted cells. *Statistically significant at p < 0.05.
AnxA6 modulation of EGFR in MDA-MB-231 cells and BT-549 cells are cell type specific and presumably dictated by the level of AnxA6 expression.

It is well established that activated EGFR is endocytosed and either degraded in lysosomes or recycled back to the cell surface [30,32,40]. It has also been shown that receptors localized at the cell surface are more efficient in eliciting downstream signaling than those localized in endocytic compartments [41,42]. The strong activation of EGFR in the AnxA6-low MDA-MB-468 cells with relatively reduced activation of ERK1/2 is consistent with the localization of activated EGFR in the perinuclear/endocytic compartment as opposed to plasma membrane localized activated EGFR. The plasma membrane localization of activated receptor correlates with robust activation of ERK1/2 in the AnxA6-high BT-549 cells. From previous studies that demonstrated that both EGFR [33,35,43] and AnxA6 [17,44,45] are components of lipid rafts and that EGFR activation occurs in lipid rafts [35], it appears that the AnxA6-dependent membrane stabilization of activated EGFR occurs mainly in lipid rafts. Therefore, the low levels of activated EGFR on the surface of MDA-MB-468 or HCC1806 cells and the reduced levels of activated receptor in AnxA6-depleted BT-549 cells may be attributed to the absence or disruption of AnxA6-stabilized lipid rafts in these cells.

The development of resistance to TKIs is common and represents a major impediment to targeted treatments with these compounds. A recent study demonstrated that localization of EGFR in lipid rafts enhanced the resistance of tumor cells to gefitinib [33]. Consistent with this report, we also showed that AnxA6-depleted BT-549 cells were more sensitive to lapatinib and PD153035 EGFR-targeted TKIs. This increase in the response of AnxA6-depleted cells to EGFR-targeted TKIs may be attributed to the disruption of AnxA6-stabilized lipid rafts and the accompanying instability of activated EGFR. Although further studies are warranted, AnxA6 expression status may underlie a novel mechanism for the development of resistance to EGFR-targeted therapies. Pending validation, patients with the more aggressive basal-like breast cancers in which AnxA6 expression is low may be more likely to respond to some EGFR-targeted therapies.

The growing evidence that AnxA6 expression promotes cell migration but attenuates cell proliferation [5,7] implies that this tumor suppressor plays an important role in breast cancer progression and/or patient survival. This also suggests that AnxA6 expression is associated with cell motility while reduced AnxA6 expression is associated with enhanced tumor cell growth. Given that AnxA6 expression is lower in breast cancer, it was necessary to assess whether AnxA6 expression status is associated with patient outcome. We provide evidence suggesting that reduced AnxA6 expression is significantly associated with higher recurrence-free but lower distant metastasis-free (DMFS) and overall survival of patients with basal-like breast cancer. Basal-like breast cancers are highly aggressive cancers with early patterns of relapse and metastasis to visceral organs [46]. The association of AnxA6 expression status with the survival of patients with this breast cancer subtype is consistent with the modulation of the stability of activated EGFR in invasive breast cancer cells by AnxA6.

Analysis of more than 200 studies involving more than 20,000 patients revealed that the expression of EGFR was also associated with reduced recurrence-free survival in patients with head and neck, ovarian, cervical, bladder and esophageal cancers. However, EGFR expression was found to exert only a modest prognostic value in other cancers including breast cancer [15]. The low prognostic value was suggested to be due to the correlation of patient survival with the total rather than the activated receptor [15]. It is also possible that this is due to the fact that EGFR activation and activity are modulated by other cellular factors including scaffolding proteins such as MUC4 [16] and AnxA6 [17-20]. The poorer distant metastasis-free and overall survival of patients with low AnxA6-expressing basal-like breast cancers could be attributed to the potentially more aggressive growth of the tumors and/or secondary lesions. On the other hand, and as demonstrated in this study, the better recurrence-free survival of low AnxA6-expressing basal-like breast cancer patients may be due to the their greater probability to respond to targeted therapy.

**Conclusions**

In summary, our study is the first to describe an association between a member of the calcium-dependent membrane binding annexin family and survival of patients affected by the highly aggressive basal-like breast cancer. This study demonstrates that the enhanced degradation of activated EGFR in AnxA6-depleted invasive breast cancer cells underlies their sensitivity to EGFR-targeted TKIs and attenuated motility. Further studies are warranted to provide a rationale for the use of AnxA6 expression status as a predictive marker for basal-like breast cancer and to identify patients with this breast cancer subtype who are more likely to respond to EGFR-targeted therapies.

**Methods**

**Cell lines and cell culture**

The following breast cancer cell lines BT-549, MDA-MB-231 (MDA-MB-231), HCC1806 were purchased from American Type Culture Collection (ATCC). MDA-MB-468
(MDA-MB-468) cells were kindly provided by Dr Ann Richmond, Vanderbilt Medical Center (Nashville, TN). These cell lines were cultured in DMEM/F12 containing 10% FBS, penicillin (100 units/ml), and streptomycin (50 units/ml). Cells were maintained at 37°C in a humidified CO₂ incubator. Where indicated, serum-starvation of cells was achieved by culturing the cells in DMEM/F12 containing 0.5% FBS for 24 to 48 h.

Antibodies and other reagents
Antibodies against EGFR, phospho-EGFR (pY1068), phospho-extracellular signal-regulated kinase 1/2 (pERK1/2, T202/Y204) and phospho-Akt (pS473) were purchased from Cell Signaling Technology (Beverly, MA, USA). Antibodies against ERK2, Akt1, GAPDH and AnxA6 were purchased from Santa Cruz Biotechnology, Inc. Antibodies specific for the flag-epitope (anti-flag M2), β-tubulin and β-actin were obtained from Sigma. Except otherwise indicated, secondary anti-mouse, anti-goat and anti-rabbit horseradish peroxidase-conjugated antibodies were purchased from Santa Cruz Biotechnology, Inc or Sigma. EGFR Tyrosine Kinase Inhibitor Set including canertinib, gefitinib, lapatinib ditosylate and erlotinib hydrochloride, gefitinib, lapatinib ditosylate and canertinib, chased from Santa Cruz Biotechnology, Inc or Sigma. Antibodies against ERK2, Akt1, GAPDH and AnxA6 were purchased from Santa Cruz Biotechnology, Inc or Sigma. PD153035 hydrochloride was purchased from BioVision Inc. Sulfo-NHS-biotin and protease inhibitor cocktail were purchased from Sigma. Except otherwise indicated, secondary anti-mouse, anti-goat and anti-rabbit horseradish peroxidase-conjugated antibodies were purchased from Santa Cruz Biotechnology, Inc or Sigma. EGFR Tyrosine Kinase Inhibitor Set including canertinib, gefitinib, lapatinib ditosylate and erlotinib hydrochloride, gefitinib, lapatinib ditosylate and canertinib, chased from Santa Cruz Biotechnology, Inc or Sigma. PD153035 hydrochloride was purchased from BioVision Inc. Sulfo-NHS-biotin and protease inhibitor cocktail were products from Sigma.

Plasmid constructs and transfections
Small hairpin RNAs (shRNAs) targeting the coding sequence of AnxA6 in pGIPZ lentiviral vector, a non-silencing shRNA control or the empty vector (Open Biosystems Inc.), were used to transfect BT-549 and MDA-MB-231 BCCs using Lipofectamine 2000 (Invitrogen). The cells were selected with puromycin 48 h post-transfection for up to three weeks. Cells expressing high levels of GFP were then sorted by flow cytometry, cloned by limiting dilution, and the isolated clones were expanded in selection medium containing puromycin (2 μg/ml). The following shRNA sequences were used to target AnxA6 in BT-549 and MDA-MB-231 cells: A6sh2, 5'- TTCA CG CATT GGT C CGA GTG-3'; A6sh5, 5'- TGT GTC TTT C TC GT CAG TCCC G-3'. For experiments involving over expression of AnxA6, the coding sequence of AnxA6 variant 1 (accession No. NM_001155.4) was amplified from plasmid pCMV-Sport6-AnxA6 (Open Biosystems Inc.). The fragment was cloned into Hind III and Xho I linearized pCMV-3Tag-8 (Clontech), and the construct used to transfect the AnxA6-low HCC1806 BCCs using Fugene6 transfection reagent (Promega). The transfected cells herein designated 1806-Anx6 and 1806-EV were selected with hygromycin, cloned as above and expanded in continued hygromycin (100 μg/ml) selection.

Immunoﬂuorescence microscopy
Cells were plated sparsely on glass cover slips and allowed to grow until they formed colonies of a few cells. Cells were then serum-starved overnight and treated with or without EGF for 5 min. Indirect immunoﬂuorescence staining was performed as previously described [5] using pEGFR (Y1068) antibodies and FITC-conjugated secondary antibodies. Cover-slips were mounted with ProLong Gold antifade containing DAPI (Invitrogen). Images were captured using a Nikon A1R confocal microscope with 60× oil-immersion objectives and analyzed using the NIS software.

Cell-surface biotinylation and Western blotting
Cells were grown in complete medium until they were 70% confluent, then serum-starved for 24 h and treated with or without EGF for the indicated time points. Following treatment, cells were washed twice with ice-cold phosphate-buffered saline (PBS) pH 7.4, with 0.5 mM Ca²⁺ and 1 mM Mg²⁺ and then incubated with Sulfo-NHS-biotin (0.2 mg/ml in cold PBS) for 30 min at 4°C. Unreacted biotin was quenched with ice-cold 100 mM glycine in PBS for 15 min at 4°C. Whole cell extracts were prepared in TNE lysis buffer (150 mm NaCl, 10 mm Tris–HCl pH 8.0, 1 mm EDTA, and 1% Nonidet P-40 with protease and phosphatase inhibitors). Biotinylated (cell surface) proteins isolated using Streptavidin-agarose beads and whole cell extracts were used for the detection of cell surface and total cellular EGFR respectively by Western blotting as previously described [5]. Immunoreactive bands were visualized by enhanced chemiluminescence (ECL; Pierce) and quantified using NIH Image J software.

Activation of EGFR and downstream signaling assays
Breast epithelial and BCCs were cultured until they were 70% confluent then serum-starved overnight and treated with 50 ng/ml EGF (EMD Biosciences) in Hank’s balanced salt solution (HBSS) for the indicated time periods. The EGF treated cells were scraped in ice-cold PBS and total cell lysates prepared as described previously [5]. EGFR activation was detected by immunoblotting with anti-EGFR (pY1068) and antibodies to total EGFR. Activation of downstream signaling cascades was determined by Western blotting using anti-pErk1/2 (pT202/pY204) and anti-pAkt (S473). Immunoblotting with antibodies to either anti-Erk2, anti GAPDH or anti-β-tubulin were used as the loading controls. Immunoreactive bands were revealed by ECL, scanned and quantified using NIH Image J software. Activation levels were determined as the ratios of phosphoprotein to the total protein or loading controls.
Cell proliferation assays
The effects of AnxA6 depletion and TKIs on cell growth were performed in 24-well plates in triplicates using 1 x 10^4 cells/well, as previously described [5]. The proliferation and viability of the cells were determined by incubating the cells in 1:10 diluted PrestoBlue reagent (Invitrogen) in HBSS supplemented with 1 mM Ca^2+ and 0.5 mM Mg^2+ for 2–4 h. Cell proliferation was determined by fluorescence measurement following excitation at 540 nm and emission at 600 nm.

Growth in 3D cultures and motility assays
Clonogenic and motility assays were performed in duplicate as previously described [5]. Digital images of the 3D cultures were captured at x10 magnification using DCM200 digital camera and Scopephoto software. For motility assays, cells were counted from at least 5 separate fields per insert.

In silico analyses
The online KM plotter was used to compare the impact of AnxA6 expression on the survival of 2,977 breast cancer patients according to the set parameters [36]. In order to analyze the prognostic value of a particular gene, the cohorts are divided into two groups according to the median (or upper/lower quartile) expression of the gene. A survival curve is displayed, and the hazard ratio with 95% confidence intervals and logrank P value are calculated and displayed [36]. We tested the effect of high or low AnxA6 expression on the overall, distant metastasis-free and recurrence-free survival of either all patients or patients with various breast cancer molecular subtypes.

Statistical analysis
Data were analyzed using Microsoft Excel 2007. Except otherwise indicated data were presented as mean ± SD. Data were analyzed using Student’s t-test; a p-value < 0.05 was considered statistically significant.

Additional files

Additional file 1: Figure S1. Down regulation of AnxA6 in BT-549 and MDA-MB-231 breast cancer cells. (A) BT-549 and MDA-MB-231 cell lines were transfected with shRNAs in pGIPZ and cloned as described in “Materials and methods”. Whole cell lysates from the isolated clones generated from two distinct shRNAs designated A6sh2 and A6sh5 were analyzed by Western blotting. Denisotometric analysis of the expression of AnxA6 relative to GAPDH is presented. B) Whole cell lysates from the selected clones were analyzed by western blotting using antibodies against AnxA6, EGFR and GAPDH.

Additional file 2: Figure S2. Differential expression of AnxA6 and EGFR-induced activation of EGFR in normal breast epithelial and breast cancer cells A) mRNA levels of AnxA6 and EGFR in normal breast epithelial and breast cancer cells. Equal amounts (1 μg) of total RNA extracted from the indicated cell lines were used for the first strand synthesis and quantitative PCR was programmed with 10% of the first strand reactions. Bars represent gene expression levels normalized to GAPDH ± s.d. from three independent determinations. (B) AnxA6 expression and EGFR-induced activation of EGFR and downstream signaling in normal and breast carcinoma cell lines. The indicated cell lines were grown to 70% confluency, followed by serum starvation for 24 h. Cells were then treated with EGF for 0-90 min and harvested by scraping in ice-cold PBS. Equal amounts of whole cell lysates were separated in 4-12% polyacrylamide gels under reducing conditions and analyzed by Western blotting using the indicated antibodies.

Additional file 3: Figure S3. Over-expression of AnxA6 in HCC1806 enhances the expression of EGFR but inhibits receptor activation and anchorage-independent growth. (A) Control (HCC1806-EV) and AnxA6 over-expressing HCC1806 (HCC1806-AnxA6) cells were grown to 70% confluency and serum-starved for 24 h. Cells were then treated with EGF for 0–90 min, and whole cell lysates were analyzed by western blotting using the indicated antibodies. End.AnxA6 = endogenous AnxA6 (B) Denisotometric analysis of AnxA6 and EGFR protein expression. Expression levels in control and AnxA6 over-expressing HCC1806 cells were normalized to GAPDH. Bars represent AnxA6 or EGFR protein expression ± s.d. from three independent experiments relative to the levels in control cells. (C) Denisotometric analysis of activated EGFR. Points represent phospho-EGFR remaining at the indicated times from a representative experiment. (D) Denisotometric analysis of activated ERK1/2. Points represent phospho-ERK1/2 levels at the indicated times from a representative experiment. (E) 3D Matrigel growth assays. Control and AnxA6 over-expressing HCC1806 cells (5 x 10^3 cells/assay) were cultured in 3D matrigel cultures for up to 10 days. Digital images of the colonies were captured with a digital camera (x10 magnification).

Abbreviations
AnxA6: Annexin A6; BCCs: breast cancer cells; BLBC: basal-like breast cancer; TNBC: triple negative breast cancer; EGFR: epidermal growth factor receptor; TKI: tyrosine kinase inhibitors; OS: overall survival; RFS: relapse-free survival; DMFS: distant metastasis-free survival.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
RK was responsible for the execution, data interpretation and data analyses; GN and PT were responsible for cell line maintenance; VA and AS were responsible for the KM survival analyses; IO contributed to experimental design and editing of the manuscript; AS directed the experimental design and provided insight for experimental execution, and drafting of the manuscript and figures; All authors have read and approved the final manuscript.

Acknowledgements
This work is supported by National Institutes of Health grant SCC2-CA170244-01 to Dr. Amos M. Sakwe and 5U54CA163069-03 (stipend to RBK). We thank Dr. Lynn Matrisian of the Pancreatic Action Network for her support and mentorship (to AS). We also thank Dr. Ann Richmond, of Vanderbilt University, Nashville TN and Drs. Ifeanyi Arinze and Diana Marver of Meharry Medical College, Nashville TN for critically reading the manuscript.

Author details
1Department of Biochemistry and Cancer Biology, Meharry Medical College, 1005 Dr. DB Todd Jr. Blvd, Nashville, TN 37208, USA. 2Division of Surgical Oncology & Endocrine Surgery, Vanderbilt University Medical Center, Nashville, TN 37232, USA. 3Department of Family and Community Medicine, Meharry Medical College, Nashville, TN 37208, USA.

Received: 7 September 2013 Accepted: 16 December 2013
Published: 19 December 2013

References
1. Buzhytnyky N, Golczak M, Lai-Kee-Him J, Lambert O, Tessier B, et al. Annexin-A6 presents two modes of association with phospholipid membranes. A combined QCM-D, AFM and cryo-TEM study. J Struct Biol 2009, 168:107–116.
2. Song G, Campos B, Wagoner LE, Dedman JR, Walsh RA: Altered cardiac annexin mRNA and protein levels in the left ventricle of patients with end-stage heart failure. J Mol Cell Cardiol 1998, 30:443–451.
3. Ueng KC, Lin CS, Yeh HI, Wu YL, Liu RH, et al: Downregulated cardiac annexin VI mRNA and protein levels in chronically fibrillating human atria. Cardiovasc Pathol 2008, 17:259–265.
4. Francis G, Mitchell SD, Moss SE, Hanby AM, Marshall JF, et al: Identification by differential display of annexin-V, a gene differentially expressed during melanoma progression. Cancer Res 1996, 56:3885–3888.
5. Sakwe AM, Koumango Sy, Guillery B, Ouchi M. Annexin A6 contributes to the invasiveness of breast carcinoma cells by influencing the organization and localization of functional focal adhesions. Exp Cell Res 2011, 317:203–207.
6. Song G, Harding SE, Dutchen MR, Turwell R, O’Gara P, et al: Altered mechanical properties and intracellular calcium signaling in cardiomyocytes from annexin VI null-mutant mice. FASEB J 2002, 16:622–624.
7. Monastyrskaya K, Babychuk EB, Hootstetter A, Wood P, Grewal T, et al: Plasma membrane-associated annexin A6 reduces Ca2+ entry by stabilizing the cortical actin cytoskeleton. Biochem Biophys Res Commun 2008, 254:1722–1724.
8. Wu CY, Taneyhill LA, Annexin A6 modulates chick cranial neural crest cell emigration. PLoS One 2012, 7(4):e49033.
9. Minashima T, Small W, Moss SE, Kirsch T: Intracellular modulation of signaling pathways by annexin A6 regulates terminal differentiation of chondrocytes. J Biol Chem 2007, 282:14803–14815.
10. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, et al: Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008, 14:1368–1376.
11. Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, et al: Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 2009, 15:2362–2370.
12. Tan DS, Matcho CJ, Jones RL, Savage K, Smith E, et al: Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-based treatment. Breast Cancer Res Treat 2009, 111:57–64.
13. Arteaga CL: Targeting HER/EGFR: a molecular approach to cancer therapy. Semin Oncol 2003, 30:3–14.
14. Baselga J: The EGFR as a target for anti-cancer therapy—focus on cetuximab. Eur J Cancer 2001, 37(Suppl 4):S16–S22.
15. Nicholson RI, Gee JM, Harper ME: EGFR and cancer prognosis. Eur J Cancer 2001, 37(Suppl 4):S59–S5
16. Mukhopadhyay P, Lakshmanan I, Ponnusamy MP, Chakraborty S, Jain M, et al: Novel biphasic traffic of endogenous EGFR to recycling and degradative compartments in lacrimal gland acinar cells. J Cell Physiol 2004, 199:108–125.
17. Wu CY, Taneyhill LA: Annexins in cell membrane dynamics. Cell Biol Int 2011, 35:351–355.
18. Corry R, Rentero C, Enrich C, Grewal T, Gaus K: Annexin VI interacts with cholesterol rich membranes in a Ca2 + and lipid dependent manner. Biochim Biophys Acta 2012, 1821:216–222.
19. Glovsky MM, Besson F, Bandorowicz-Pikula J: Evidence for self-association and binding to actin. FEBS Lett 2000, 469:88–92.
20. Koese M, Rentero C, Kota PB, Hoque M, Cairns R, et al: Annexin A6 is a scaffold for PKCalpha to promote EGFR inactivation. Oncogene 2013, 32:2858–2872.
21. Babychuk EB, Palstra R, Schaller J, Kampfer U, Draeger A, Arteaga CL: Annexin VI participates in the formation of a reversible, membrane-cytoskeleton complex in smooth muscle cells. J Biol Chem 1999, 274:35911–35916.
22. Locate S, Colyer J, Gawler DJ, Walker JH: Annexin A6 at the cardiac myocyte sarcolemma—evidence for self-association and binding to actin. Cell Biol Int 2008, 32:1388–1396.
23. Ortega D, Pol A, Biemer M, Jäckle S, Enrich C: Annexin VI defines an apical endocytic compartment in rat liver hepatocytes. J Cell Sci 1998, 111(Pt 2):261–269.
24. Pons M, Grewal T, Rius E, Schnietermans T, Jackel S, et al: Evidence for the localization of annexin 6 in the trafficking between the endocytic compartment and lysosomes. Exp Cell Res 2001, 269:13–22.
25. Gyorffy B, Benke Z, Lanczky A, Balazs B, Szallasi Z, et al: Integrated analysis of breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-based treatment. Breast Cancer Res Treat 2010, 128:51–62.
26. Blanco MA, Aleckovic M, Hua Y, Li T, Wei Y, et al: Identification of staphylococcal nuclease domain-containing 1 (SND1) as a Metadherin-interacting protein with metastasis-promoting functions. J Biol Chem 2011, 286:19982–19992.
27. Domon MM, Besson F, Bandorowicz-Pikula J: Reduced annexin A6 expression promotes the degradation of activated epidermal growth factor receptor and sensitizes invasive breast cancer cells to EGFR-targeted tyrosine kinase inhibitors. Mol Cancer Ther 2013, 12:167.